Literature DB >> 33409786

Dixon-T2WI magnetic resonance imaging at 3 tesla outperforms conventional imaging for thyroid eye disease.

Alexis Ollitrault1, Frédérique Charbonneau2, Marie-Laure Herdan3, Olivier Bergès2, Kevin Zuber4, Lama Giovansili5, Pauline Launay5, Julien Savatovsky2, Augustin Lecler2.   

Abstract

OBJECTIVES: To determine the diagnostic performances of a single Dixon-T2-weighted imaging (WI) sequence compared to a conventional protocol including T1-, T2-, and fat-suppressed T2-weighted MRI at 3 T when assessing thyroid eye disease (TED).
MATERIALS AND METHODS: This IRB-approved prospective single-center study enrolled participants presenting with confirmed TED from April 2015 to October 2019. They underwent an MRI, including a conventional protocol and a Dixon-T2WI sequence. Two neuroradiologists, blinded to all data, read both datasets independently and randomly. They assessed the presence of extraocular muscle (EOM) inflammation, enlargement, fatty degeneration, or fibrosis as well as the presence of artifacts. The Wilcoxon signed-rank test was used.
RESULTS: Two hundred six participants were enrolled (135/206 [66%] women, 71/206 [34%] men, age 52.3 ± 13.2 years). Dixon-T2WI was significantly more likely to detect at least one inflamed EOM as compared to the conventional set (248/412 [60%] versus 228/412 [55%] eyes; (p = 0.02). Dixon-T2WI was more sensitive and specific than the conventional set for assessing muscular inflammation (100% versus 94.7% and 71.2% versus 68.5%, respectively). Dixon-T2WI was significantly less likely to show major or minor artifacts as compared to fat-suppressed T2WI (20/412 [5%] versus 109/412 [27%] eyes, p < 0.001, and 175/412 [42%] versus 257/412 [62%] eyes, p < 0.001). Confidence was significantly higher with Dixon-T2WI than with the conventional set (2.35 versus 2.24, p = 0.003).
CONCLUSION: Dixon-T2WI showed higher sensitivity and specificity and showed fewer artifacts than a conventional protocol when assessing thyroid eye disease, in addition to higher self-reported confidence. KEY POINTS: • Dixon-T2WI has better sensitivity and specificity than a conventional protocol for assessing inflamed extraocular muscles in patients with thyroid eye disease. • Dixon-T2WI shows significantly fewer artifacts than fat-suppressed T2WI. • Dixon-T2WI is faster and is associated with significantly higher self-reported reader confidence as compared to a conventional protocol when assessing inflammatory extraocular muscles.

Entities:  

Keywords:  Artifacts; Eye diseases; Magnetic resonance imaging; Thyroid diseases

Year:  2021        PMID: 33409786     DOI: 10.1007/s00330-020-07540-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy.

Authors:  Seigo Tachibana; Tsukasa Murakami; Hitoshi Noguchi; Yasushi Noguchi; Akiko Nakashima; Yufuko Ohyabu; Shiro Noguchi
Journal:  Endocr J       Date:  2010-08-19       Impact factor: 2.349

Review 2.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

3.  Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg.

Authors:  Letterio Salvatore Politi; Claudia Godi; Gabriella Cammarata; Alessandro Ambrosi; Antonella Iadanza; Roberto Lanzi; Andrea Falini; Stefania Bianchi Marzoli
Journal:  Eur Radiol       Date:  2014-02-12       Impact factor: 5.315

4.  Simple proton spectroscopic imaging.

Authors:  W T Dixon
Journal:  Radiology       Date:  1984-10       Impact factor: 11.105

5.  Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Katsutaro Morino; Satoshi Ugi; Yoshihiko Nishio; Hiroshi Maegawa; Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2014-12-03       Impact factor: 2.447

6.  Disease activity in Graves' ophthalmopathy: diagnosis with orbital MR imaging and correlation with clinical score.

Authors:  Fabio Tortora; Mario Cirillo; Marco Ferrara; Maria Paola Belfiore; Carlo Carella; Ferdinando Caranci; Sossio Cirillo
Journal:  Neuroradiol J       Date:  2013-11-07

7.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

Review 8.  Extrathyroidal manifestations of thyroid disease: thyroid ophthalmopathy.

Authors:  Hemant Parmar; Mohannad Ibrahim
Journal:  Neuroimaging Clin N Am       Date:  2008-08       Impact factor: 2.264

9.  Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity.

Authors:  Cesare Gagliardo; Stefano Radellini; Raffaella Morreale Bubella; Giorgia Falanga; Pierina Richiusa; Maria Vadalà; Alessandro Ciresi; Massimo Midiri; Carla Giordano
Journal:  Eur Radiol       Date:  2020-01-17       Impact factor: 5.315

10.  Quantitative Analysis of Inflammation in Orbital Fat of Thyroid-associated Ophthalmopathy Using MRI Signal Intensity.

Authors:  Tomoaki Higashiyama; Maki Iwasa; Masahito Ohji
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

View more
  2 in total

1.  Radiomics analysis of the optic nerve for detecting dysthyroid optic neuropathy, based on water-fat imaging.

Authors:  Hongyu Wu; Ban Luo; Yali Zhao; Gang Yuan; Qiuxia Wang; Ping Liu; Linhan Zhai; Wenzhi Lv; Jing Zhang
Journal:  Insights Imaging       Date:  2022-09-24

2.  Current insights of applying MRI in Graves' ophthalmopathy.

Authors:  Cheng Song; Yaosheng Luo; Genfeng Yu; Haixiong Chen; Jie Shen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.